05:40 AM EDT, 06/14/2024 (MT Newswires) -- Gilead Sciences' ( GILD ) Kite unit said Friday that results from three new analyses of Yescarta, or axicabtagene ciloleucel, in relapsed/refractory large B-cell lymphoma demonstrated the potential benefit of using the product candidate in earlier lines of treatment in terms of both manufacturing success and product characteristics.

New data include the results from a comparative analysis of real-world and clinical trial data, which showed Yescarta's higher manufacturing success rate and improved T-cell performance in second-line treatment compared with third-line, said the company. Data also support the safety and feasibility of Yescarta's outpatient administration, Kite added.

Kite presented the new data at a recent medical event in Spain.

Price: 63.62, Change: +0.06, Percent Change: +0.09